Author

M. I. Braghiroli

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.

BACKGROUND Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC). We report OS and additional analyses at a minimum follow-up of 5 years....

K. Kato, J. Ajani, Y. Doki et al. · Annals of Oncology · 2 citations

Open access Aug 2026

Diagnosis, clinical assessment, and staging of hepatocellular carcinoma: a Brazilian multidisciplinary consensus

ABSTRACT Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with a rising incidence largely driven by chronic liver disease. Accurate diagnosis and appropriate clinical assessment at the time of presentation are essential, as therapeutic strategies and prognosis depend...

F. Coimbra, André Luís de Godoy, P. H. de Sousa Fernandes et al. · Arquivos brasileiros de ciru... · 0 citations

Review Aug 2026

Immunotherapy in Colorectal Cancer: Novel Perspectives and Next Steps.

Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide and the second leading cause of cancer-related mortality. Currently, only about 15% of newly diagnosed CRC cases and 5% of metastatic cases are classified as being microsatellite instability-high (MSI-H) and can benefit significantly from imm...

Thaís Sampaio Corrêa de Almeida, M. I. Braghiroli, J. Sabbaga et al. · American Journal of Clinical... · 0 citations